This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biochemicalassays are commonly used to assess how organic compounds impact the activity of a protein of interest (POI). Het bericht Positive Impact of Dragonfly™ Discovery in BiochemicalAssay verscheen eerst op ZoBio - Drug Discovery Technology.
A number of peptidomimetic Mpro inhibitors have been described in the literature and this blog post by Chris Southan may be of interest. Here’s a blog post by Pat Walters in which he examines the structure-activity relationships emerging for the fragment-derived inhibitors.
Biochemicalassays have the highest success rate. The top 20 Pharma are moving away from proteins in biochemicalassays and overexpressed targets in simple cell lines toward more physiologically relevant assays using primary cells, cocultures, 3-D cell systems, or organoids. Biologics are booming. Think again.
As is usual for blog posts here at Molecular Design , quoted text is indented with my comments enclosed in square brackets in red italics. These include the following: Different assay conditions: these can include different buffers, experimental pH, temperature, and duration.
Additionally, Strateos' Senior Director of R&D Strategy, Daniel Rines, Ph.D., will be participating in a panel discussion during SLAS2022 February 7th 4:30-6:00pm EST alongside other thought leaders to discuss artificial intelligence in labs now and in the future.
Recent blog posts from Greg Landrum examined the impact of combining IC50 and Ki data from different assays. While Greg found that combining data from Ki assays is sometimes acceptable, the situation with IC50 data was more dire. For example, the widely used MoleculeNet BACE dataset was collected from 55 papers.
I’ll make some comments on PAINS filters before I discuss B2023 in detail and much of what I’ll be saying has already been said in K2017 and C2017 (Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS) although you shouldn’t need to consult these articles in order to read the blog post unless you want to get some (..)
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content